614PCANYON trial results: sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMD
Year: 2025
Type: article
Source: Neuromuscular Disorders
Authors: C. McDonald, H. Kushlaf, D. Castro, K. Mathews, A. Varadhachary, A. Connolly, M. Guglieri, D. Leung, J. Statland, E. Niks, R. Quinlivan, V. Sreenivasan, A. Veerapandiyan, N. Johnson, H. Phan, B. Wong, R. Dreghici, J. MacDougall, A. Russell, J. Donovan
Institutions: University of California, Davis, University of Cincinnati, University of Iowa, Washington University in St. Louis, Nationwide Children's Hospital, Newcastle University, Kennedy Krieger Institute, University of Kansas Medical Center, Leiden University Medical Center, National Hospital for Neurology and Neurosurgery, University of Colorado Denver, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Virginia Commonwealth University, UMass Memorial Medical Center, Edgewise Therapeutics (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4414824077